Venture-Backed Startups

Ability.ai builds AI agents that automate repetitive, rule-based workflows across business functions like customer support, HR, marketing, sales, finance, and IT, which customers deploy on their own platform called Trinity. The company serves operations-heavy sectors including staffing, e-commerce, SaaS, marketing agencies, logistics, and manufacturing.

1 investor

0 investors

AbilityPharma develops innovative oncology therapies that induce autophagy to treat various cancers and address unmet medical needs. The company has advanced therapies including ibrilatazar (ABTL0812) through clinical trials for lung cancer, pancreatic cancer, and other tumor types.

3 investors

Vegan food and sustainable product reviews

3 investors

Abingdon Software provides software solutions to public and private sector organisations. The company reports serving more than 2,000 organisations globally.

3 investors

Abingdon Health is a contract developer and manufacturer of rapid lateral flow diagnostic tests, serving healthcare, animal health, and plant health sectors. It provides services from biomarker validation through FDA submission, scale-up, and large-scale manufacturing, and also supplies its own lateral flow test brands to consumers, retail, wholesale, and distributors globally.

2 investors

Abingworth is a venture capital and private equity firm specializing in life sciences and healthcare investments across seed, development, and clinical co-development stages. The firm manages 15 dedicated funds and has invested in over 200 companies across the United States and Europe.

1 investor

AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.

1 investor

1 investor

ABio-X is a life sciences incubation platform that creates and invests in biotech and pharmaceutical companies developing innovative medicines and technologies. The platform provides capital, operational support, and access to experienced entrepreneurs and industry networks to accelerate drug development pipelines.

1 investor

Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.

1 investor

Abion is a biotech company focused on precision oncology, researching and developing novel anticancer drugs. It works to identify and commercialize new drug candidates and conduct global clinical trials for rare and hard-to-treat diseases, partnering with domestic and international biopharma companies.

5 investors

Abionic develops the abioSCOPE, a near-patient rapid diagnostic platform that uses nanofluidic immunoassay technology to deliver lab-quality results from a single drop of blood within minutes. The platform is designed for clinical settings including hospitals and laboratories to enable early detection of conditions such as sepsis.

1 investor

ABIONYX Pharma is a biotech company developing therapies for diseases with no effective or existing treatment, including rare conditions. Its focus areas include drugs for renal and ophthalmological diseases and HDL-based vectors for targeted drug delivery.

1 investor

Abios provides enterprise-scale esports betting data, odds, and widgets to licensed operators and media companies in regulated markets globally. The company leverages machine learning and statistical analysis to power esports solutions.

1 investor

Abiquo offers a hybrid and multi-cloud management platform that lets managed service providers, telecom companies, and enterprises control public and private cloud resources from a single console, with FinOps cost management, automation, and an XaaS marketplace. Its XaaS marketplace enables MSPs and CIOs to deliver applications, managed services, and third-party SaaS offerings through a self-service portal.

2 investors

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

6 investors

AbiVC offers a venture platform that automates dealflow management for investors, including auto-qualifying inbound opportunities, managing founder communication, and running automated due diligence. It also provides founders with "Abi," a digital co-founder tool to manage communication and due diligence.

1 investor

Abivo builds AI-driven accounts receivable software that handles overdue invoice outreach with a customer-focused, human-like approach. It targets businesses managing A/R processes.

2 investors

ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer. Spun out of Dalhousie University, it serves interventional oncology and radiology applications.

3 investors

0 investors

ABL Bio develops biotherapeutic drugs using dual antibody platform technology for immunotherapy cancer treatments and degenerative neurological diseases. The company is a South Korea-based biotech research firm with proprietary platforms designed to treat intractable diseases.

2 investors

ABL Health is a community-based healthcare organisation focused on eradicating health inequalities by supporting people to become active participants in their own health. The organisation works with local communities and the wider healthcare system in the UK to deliver evidence-based health and wellbeing services.

1 investor

ABL Space Systems builds small satellite launch vehicles and a containerized launch system designed to enable orbital launches from flat pads in different locations. Its offerings target customers needing transportable, lower-cost access to space.

4 investors